You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2025

Patent: 10,111,900


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,111,900
Title:.beta.-glucan methods and compositions that affect the tumor microenvironment
Abstract: This disclosure relates to the combination of soluble .beta.-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble .beta.-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
Inventor(s): Bose; Nandita (Plymouth, MN), Gorden; Keith (Woodbury, MN), Chan; Anissa Sh. (Arden Hills, MN), Leonardo; Steven (Rosemount, MN), Graff; Jeremy (Indianapolis, IN), Qiu; Xiaohong (Edina, MN), Kangas; Takashi (Shoreview, MN), Fraser; Kathryn A. (St. Paul, MN), Bykowski Jonas; Adria (Eden Prairie, MN), Ottoson; Nadine (Lakeville, MN), Fulton; Ross (St. Paul, MN)
Assignee: BIOTHERA, INC. (Eagan, MN)
Application Number:15/386,781
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of United States Patent 10,111,900: Navigating the Patent Landscape

Introduction

Understanding the intricacies of a patent, particularly one like United States Patent 10,111,900, involves a multifaceted analysis that delves into the patent's claims, the broader patent landscape, and the relevant sections of U.S. Patent Law. This article will provide a detailed examination of these aspects, highlighting key points and strategic considerations.

Understanding the Patent Claims

To begin, it is crucial to analyze the claims of the patent in question. The claims define the scope of the invention and are the basis for determining patentability.

Claim Structure and Scope

  • Claim Types: Identify whether the claims are directed towards processes, machines, manufactures, or compositions of matter. This is essential under Section 101 of U.S. Patent Law, which sets forth what constitutes patentable subject matter[1][2].
  • Specificity and Clarity: Ensure that the claims are specific, clear, and concise. This helps in avoiding issues related to abstract ideas and ensures that the claims meet the requirements of Section 112, which deals with the clarity and definiteness of the claims[2].

Section 101 – Patentable Subject Matter

Definition and Overview

Section 101 is foundational in U.S. Patent Law, defining what can be patented. It includes new and useful processes, machines, manufactures, or compositions of matter, or any new and useful improvement thereof[1].

Judicial Exceptions

  • Laws of Nature, Natural Phenomena, and Abstract Ideas: These are not patentable. The Supreme Court's decision in Alice Corp. v. CLS Bank International established a two-part test to determine if a claim is directed to an abstract idea and whether the other elements of the claim transform it into patent-eligible subject matter[1][2].

Practical Insights for Section 101

  • Aligning Innovations: Focus on the tangible and applicable aspects of the invention. Provide clear, concrete embodiments and detail the practical applications to avoid issues related to abstract ideas[1].
  • Precision in Patent Applications: Clearly articulate how the invention operates in a specific, tangible manner. This aids in navigating the nuances of Section 101[1].

Section 102 – Novelty and Prior Art

Definition and Overview

Section 102 deals with the novelty of the invention and the loss of the right to a patent. It ensures that the invention is new and not obvious in light of prior art[1][2].

Determining Novelty

  • Prior Art Analysis: Conduct a comprehensive analysis of prior art to ensure the invention is novel. This involves identifying existing patents and publications that could affect the patentability of the claims[3].

Practical Insights for Section 102

  • First-to-File Principles: Understand the importance of being the first to file, as this can impact the novelty of the invention. Incremental yet impactful innovations can still secure patent rights if they demonstrate commercial success and distinctiveness[1].

Section 103 – Non-obviousness

Definition and Overview

Section 103 focuses on non-obviousness, ensuring that the invention is not readily apparent to a person having ordinary skill in the art (PHOSITA)[1].

Determining Non-obviousness

  • Multifaceted Analysis: Assess several factors, including the differences from prior art, the level of ordinary skill in the art, and any secondary considerations such as commercial success or unexpected results[1].

Practical Insights for Section 103

  • Strategic Patent Drafting: Craft patent applications that clearly differentiate the inventive steps from prior art. Meticulous illustration of the differences is essential[1].
  • In-depth Prior Art Analysis: Comprehensive knowledge of existing prior art helps in anticipating potential objections on obviousness grounds and in framing robust arguments and claims[1].

Patent Landscape Analysis

Overview

A patent landscape analysis provides a comprehensive view of the patent space, helping in strategic decision-making.

Key Questions to Answer

  • Geographical Spread: Determine the geographical distribution of patents in the relevant technology area[3].
  • Saturation: Assess the level of saturation in the patent space to identify potential areas for innovation[3].
  • New Entrants: Identify new entrants into the patent space and their impact on the market[3].
  • Time-Slicing: Analyze changes over time to understand trends and shifts in the technology area[3].

Strategic Insights

  • High-Level Approach: A comprehensive patent landscape analysis helps in making long-term decisions about technology pivots and identifying underappreciated niche areas[3].
  • Beyond Known Competitors: Look beyond known competitors to uncover hidden trends and opportunities in the patent landscape[3].

Case Study: Alice Corp. v. CLS Bank International

The Alice Corp. v. CLS Bank International decision is pivotal in understanding Section 101.

Two-Part Test

  • Step 1: Determine if the claim is directed to a process, machine, manufacture, or composition of matter.
  • Step 2A: If yes, determine if the claim is directed to a law of nature, natural phenomenon, or abstract idea. If so, proceed to Step 2B.
  • Step 2B: Determine if the other elements of the claim transform the claim into patent-eligible subject matter[1][2].

Practical Tips for Overcoming Section 101 Rejections

Prong Two of Step 2A

  • Practical Applicability: Demonstrate that the claims are directed to a specific, concrete technological advancement or solution to a technical problem. This is particularly important for AI inventions[4].

The Role of USPTO Guidelines and Updates

Deferred Approach to Section 101 Analysis

  • Proposed by Senators: The proposal to defer Section 101 analysis until the traditional analysis under Sections 102, 103, and 112 is undertaken aims to streamline the patent prosecution process and reduce bottlenecks[2].

Impact on Patent Prosecution

Pre- and Post-Alice Era

  • Increased Rejections: The Alice decision led to a significant increase in Section 101 rejections. However, subsequent court cases and USPTO guidelines have helped mitigate this issue[2].

Director Review Petitions and PTAB Analysis

Plant Utility Claims

  • Competition in Seed Markets: The PTAB's approach to reviewing plant utility claims can impact competition in seed markets. Ensuring that seed deposits do not unnecessarily restrict competition is crucial[5].

Key Takeaways

  • Section 101: Ensure claims are directed to patentable subject matter, avoiding judicial exceptions like abstract ideas.
  • Section 102: Conduct thorough prior art analysis to establish novelty.
  • Section 103: Demonstrate non-obviousness through clear differentiation from prior art.
  • Patent Landscape Analysis: Use comprehensive analysis to identify trends, saturation, and new entrants in the patent space.
  • Practical Applicability: Focus on concrete technological advancements to overcome Section 101 rejections.

FAQs

What is the significance of Section 101 in U.S. Patent Law?

Section 101 defines what constitutes patentable subject matter, ensuring that only new and useful processes, machines, manufactures, or compositions of matter can be patented.

How does the Alice Corp. v. CLS Bank International decision impact patent eligibility?

The Alice decision established a two-part test to determine if a claim is directed to an abstract idea and whether the other elements of the claim transform it into patent-eligible subject matter.

What is the role of prior art analysis in determining patentability?

Prior art analysis is crucial for ensuring the novelty and non-obviousness of an invention. It involves identifying existing patents and publications that could affect the patentability of the claims.

How does patent landscape analysis aid in strategic decision-making?

Patent landscape analysis provides a comprehensive view of the patent space, helping in identifying trends, saturation, new entrants, and underappreciated niche areas, which aids in making long-term decisions about technology pivots.

What are the practical tips for overcoming Section 101 rejections for AI inventions?

Demonstrate that the claims are directed to a specific, concrete technological advancement or solution to a technical problem, focusing on practical applicability under Prong Two of Step 2A.

Sources

  1. TT Consultants, "Exploring Sections 101, 102, & 103 of U.S. Patent Law," October 5, 2023.
  2. Von Briesen & Roper, s.c., "USPTO Launches Deferred Approach to Section 101 Eligibility Analysis in Patent Prosecution," February 7, 2022.
  3. AcclaimIP, "Patent Landscape Analysis - Uncovering Strategic Insights."
  4. Baker Botts, "The Importance of Prong Two of Step 2A for AI Inventions," August 26, 2024.
  5. IPWatchdog, "Director Review Petitions Charge PTAB Analysis of Plant Utility Claims Threatens Competition for U.S. Farmers," November 18, 2024.

More… ↓

⤷  Try for Free

Details for Patent 10,111,900

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 March 25, 2011 10,111,900 2034-11-06
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab For Injection 125514 September 04, 2014 10,111,900 2034-11-06
Merck Sharp & Dohme Llc KEYTRUDA pembrolizumab Injection 125514 January 15, 2015 10,111,900 2034-11-06
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 3 of 3 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.